Search Results 681-690 of 18435 for alopecia

1. My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors - Mayo Clinic

   ... alopecia; Radiation therapy within ≤ 14 days; Active or untreated brain metastases; History of carcinomatous meningitis; Uncontrolled concurrent malignancy ...

2. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Scarring alopecia, Tinea versicolor, Rosacea, Melasma, Vitiligo, Vascular malformation, Nonmelanoma skin cancer, Tuberous sclerosis ...

3. A Study to Evaluate Food on Gastrointestinal Toxicity and The Effect of Selumetinib in Adolescents with Neurofibromatosis Type 1 - Mayo Clinic

   − Have any other unresolved chronic toxicity with CTCAE Grade ≥ 2, except hair changes (such as alopecia or high lightening). Participants who have ...

4. A Study to Assess LXH254 in Patients with Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma - Mayo Clinic

   Presence of ≥ CTCAE grade 2 toxicity (except alopecia) due to prior anti-cancer therapy. Grade 2 endocrinopathies being treated with replacement therapy ...

5. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Scarring alopecia, Tinea versicolor, Rosacea, Melasma, Vitiligo, Vascular malformation, Nonmelanoma skin cancer, Tuberous sclerosis ...

6. Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas - Mayo Clinic

   ... alopecia, fatigue, and hematologic toxicities); Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to ...

7. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Scarring alopecia, Tinea versicolor, Rosacea, Melasma, Vitiligo, Vascular malformation, Nonmelanoma skin cancer, Tuberous sclerosis ...

8. A Study of JNJ-68284528, a Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Toxicity from previous anticancer therapy must resolve to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy. The following ...

9. A Study of Cediranib and Olaparib Combined, Compared to Either Drug Alone, or to a Standard Chemotherapy in Treating Patients who have a Return of Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Mayo Clinic

   Toxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per CTCAE v 4.0; Adequately controlled blood pressure ...

10. A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Participants With Prostate Cancer - Mayo Clinic

    ... alopecia or peripheral neuropathy AND have a washout period from last dose of prior systemic or radiation therapy as follows: Patients must discontinue ...